Form 4: Alkermes Executive Christian Todd Nichols Reports Share Acquisition and Disposal

Christian Todd Nichols, SVP and Chief Commercial Officer of Alkermes plc, reports acquiring shares through vesting of restricted stock units and disposing of shares to cover tax obligations.

Summary

• On February 6, 2025, Christian Todd Nichols, SVP, Chief Commercial Officer of Alkermes plc, acquired 24,565 ordinary shares due to the vesting of performance-vesting restricted stock units (PRSUs) granted on February 18, 2022.
• These PRSUs had a three-year performance period ending December 31, 2024, and their vesting was triggered by the achievement of pre-specified performance goals and a total shareholder return modifier.
• On the same day, Nichols disposed of 7,399 ordinary shares at a price of $31.39 to satisfy tax obligations.
• Following these transactions, Nichols beneficially owns 77,869 ordinary shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The vesting of performance-based awards suggests the company is meeting its goals, but the disposal of shares introduces a slightly negative element.

Positives

• The vesting of performance-based restricted stock units suggests that Alkermes achieved certain pre-specified performance goals, which is a positive indicator.
• Executive ownership of a significant number of shares (77,869) aligns management's interests with those of shareholders.

Negatives

• The disposal of shares to cover tax obligations, while common, can be perceived negatively if investors believe the executive is reducing their stake in the company.

Risks

• Executive stock transactions can sometimes be misinterpreted by the market, leading to short-term price volatility.
• Future performance may not meet the targets required for further vesting of performance-based equity awards.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of PRSUs is tied to future performance, suggesting continued focus on achieving performance goals.

Industry Context

Executive stock transactions are common in the pharmaceutical industry as part of compensation packages designed to align management incentives with shareholder value. The vesting of performance-based awards indicates that the company has met certain pre-defined targets.

Comparison to Industry Standards

• Executive compensation packages in the pharmaceutical industry often include a mix of salary, stock options, and restricted stock units.
• Performance-based vesting is a common mechanism to incentivize executives to achieve specific financial or strategic goals.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize similar equity-based compensation structures for their executives.

Stakeholder Impact

• Shareholders may view the vesting of performance-based awards as a positive sign of company performance.
• Employees may be motivated by the achievement of performance goals that trigger executive compensation.

Key Dates

Keywords

Alkermes, Nichols, stock, shares, vesting, performance, restricted stock units, Form 4, executive compensation, ALKS